Hepatitis C virus, diabetes and steatosis: Clinical evidence in favor of a linkage and role of genotypes

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 280-284

  Mihm, Sabine ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Hepatitis C virus; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANTIVIRAL ACTIVITY; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SCREENING; FATTY LIVER; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TYPING;

ANTIVIRAL AGENTS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM;

EID: 77952569599     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282103     Document Type: Review

References (29)

1. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
2. Raddatz D, Ramadori G: Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 2007;45:51-62.
3. White DL, Ratziu V, El-Serag HB: Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008;49: 831-84 4.
4. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P: Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-423.
5. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ, Kao JH, Chen DS: High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008;28:271-277.
6. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007;102:570-576.
7. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H: Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 20 09;49: 739-74 4.
8. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Sola R, Pons JA, Salmeron J, Barcena R, Perez R, Carmona I, Duran S: Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-727.
9. Saxena AK, Panhotra BR: The susceptibility of patients with type-2 diabetes to hepatitis C virus infection during long-term haemodialysis. Sw iss Med Wk ly 2003;133:611-618.
10. Machado MV, Cortez-Pinto H: Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol 2009;8(suppl 1):S67-S75.
11. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 20 06;130:1636-1642.
12. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
13. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, Theocharis GJ, Labropoulou-Karatza C: Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006;18:233-237.
14. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-577.
15. Mihm S, Fayyazi A, Hartmann H, Ramadori G: Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997;25:735-739.
16. Negro F, Sanyal AJ: Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009;29(suppl 2): 26-37.
17. Thomssen R, Bonk S, Thiele A: Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol 1993;182:329-334.
18. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A: Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992;181: 293-30 0.
19. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R: Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223-229.
20. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX: Hepatitis C virus and other flavi-viridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-12771.
21. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85. (Pubitemid 36775798)
22. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36:1266-1272.
23. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
24. Charlton MR, Pockros PJ, Harrison SA: Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-1186.
25. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE: Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008;48:80-87.
26. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F: The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007;45:1164-1171.
27. Overbeck K, Genne D, Golay A, Negro F: Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribav irin. J Hepatol 2008;49:295-298.
28. Serfaty L, Fartoux L, Poupon R: Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol 2009;50:1269-1271.
29. Lonardo A, Loria P, Bertolotti M, Carulli N: Statins and HCV: a complex issue. Hepatology 2007;45:257.